Jaguar Animal Health Q3 Earnings Call Highlights

Jaguar Animal Health (NASDAQ:JAGX) narrowed its third-quarter net loss and reduced outstanding debt by more than $10 million as it shifted its focus toward developing a treatment for rare intestinal failure conditions, executives said on an investor webcast.

The company plans to seek U.S. approval in mid-2027 for a new formulation of crofelemer to treat pediatric microvillus inclusion disease, or MVID. Jaguar has completed enrollment in a blinded pivotal trial for the ultra-rare condition, founder, President and CEO Lisa Conte said.

Jaguar also is evaluating potential partnerships and other strategic alternatives for its intestinal failure program. Conte said the company is seeking non-dilutive funding from a development or commercialization partner, following its January 2026 U.S. commercial licensing agreement with Future Pak.

Loss narrows as licensing changes revenue model

Jaguar reported a third-quarter net loss of $5.8 million, compared with $9.6 million a year earlier. Its operating loss narrowed to $6 million from $7.2 million, as a roughly $2 million reduction in operating expenses offset a $700,000 decline in total net revenue, Chief Financial Officer Carol Lizak said.

Prescription product net revenue was approximately $500,000 in the third quarter, down from $1.2 million in the second quarter and about $3 million a year earlier. Lizak said the latest quarter’s prescription revenue consisted primarily of sales of Mytesi to Future Pak at cost-plus terms.

Under the royalty-free agreement, U.S. revenue from Mytesi and Canalevia-CA1 has been directed to Future Pak effective Jan. 12, 2026. Jaguar continues to manufacture and supply both products. Mytesi is approved for adults living with HIV/AIDS and diarrhea, while Canalevia-CA1 is conditionally approved for chemotherapy-induced diarrhea in dogs.

Conte said the deal included $18 million upfront. Lizak said Jaguar satisfied the closing conditions for an approximately $1.8 million holdback from that fee in August. The number of Mytesi bottles Jaguar sold increased significantly from the third quarter of 2025, while commercial costs fell substantially, Lizak said. Future Pak is privately held and does not report Mytesi sales.

Jaguar’s non-GAAP recurring EBITDA loss was approximately $5 million, compared with $9 million a year earlier. The company also recorded a $600,000 gain on extinguishment of debt, primarily related to the cancellation of a Streeterville note following an exchange in which Jaguar issued common shares, Lizak said.

Rare disease filing targeted for 2027

Jaguar’s lead development program uses a powder-for-oral-solution formulation of crofelemer as an adjunct to parenteral support, the intravenous provision of nutrition and fluids. Conte said the aim is to reduce the time patients need that support, which can be associated with serious complications.

All randomized pediatric patients in the MVID trial have entered a single-blind extension phase and are receiving crofelemer, Conte said. The extension is intended to provide additional safety and efficacy information for the planned application. She said the submission would draw on a single-digit number of patients, including trial participants and patients treated through early-access programs.

Jaguar also plans to apply for FDA breakthrough therapy designation for crofelemer in MVID in 2027. Conte said obtaining the designation could make approval by the end of 2027 possible, though both the designation and any approval remain subject to regulatory review.

Conte pointed to previously presented results from individual patients treated under early-access programs. In one pediatric MVID patient, weekly parenteral support requirements adjusted for body weight fell by up to 48% after more than 12 months of crofelemer therapy. Two pediatric short bowel syndrome patients had reductions of up to 40% over more than a year of treatment, she said. Conte said no safety issues were reported in those patients.

Short bowel syndrome and animal health

Jaguar is also conducting a randomized, double-blind, placebo-controlled Phase 2 trial of the same formulation in adults with short bowel syndrome and intestinal failure at sites in Germany and Italy. Conte said the company expects results to become available around the time of the planned MVID application.

An investigator presented preliminary positive results from a separate ongoing, open-label pilot study in adults with the condition at the American College of Gastroenterology’s annual meeting, Conte said. She described MVID as a potential stepping stone toward approval in the larger short bowel syndrome indication.

Conte said Jaguar’s human development work is focused on rare disease, while the company retains a small animal health business. Its nonprescription Neonorm Dog product is now available on Amazon, she said, with broader animal health distribution anticipated.

About Jaguar Animal Health (NASDAQ:JAGX)

Jaguar Health, Inc., formerly Jaguar Animal Health, develops prescription medicines for gastrointestinal disorders in humans and animals. The company’s research has focused on plant-derived compounds, including crofelemer, which is derived from the Croton lechleri tree. Jaguar’s animal-health product Canalevia-CA1 received FDA conditional approval for the treatment of chemotherapy-induced diarrhea in dogs. The company also develops and commercializes crofelemer-based medicines for human gastrointestinal conditions.